# Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy

> **NCT02288741** · PHASE3 · COMPLETED · sponsor: **WiSP Wissenschaftlicher Service Pharma GmbH** · enrollment: 549 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Anthracycline/dexamethasone-based induction chemotherapy
- **DRUG:** Dexamethasone for control of symptoms
- **DRUG:** Tumor-reduction chemotherapy and stem cell mobilization
- **PROCEDURE:** Stem cell apheresis
- **DRUG:** Tandem high-dose chemotherapy (melphalan)
- **PROCEDURE:** Autologous peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT02288741
- **Lead sponsor:** WiSP Wissenschaftlicher Service Pharma GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2014-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02288741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02288741, "Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02288741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*